Induction vs. escalating therapy in Multiple Sclerosis: practical implications
Author:
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s10072-008-0954-x.pdf
Reference9 articles.
1. Comi G (2008) Clinically isolated syndrome: the rationale for early treatment. Nat Clin Pract Neurol 4:234–235
2. Mancardi G, Saccardi R (2008) Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7:626–636
3. Zipoli V, Portaccio E, Hakiki B et al (2008) Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open label comparative study of efficacy and safety. J Neurol Sci 266:25–30
4. Engelhardt B, Kappos L (2008) Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 5:16–22
5. Talar-Williams C, Hijazi YM, Walther MM et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477–484
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab;Meditsinskiy sovet = Medical Council;2024-08-15
2. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study);Current Neuropharmacology;2024-01
3. An update on combination therapies for multiple sclerosis: where are we now?;Expert Review of Neurotherapeutics;2023-12-02
4. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?;Drugs;2023-09-19
5. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS);Current Reviews in Clinical and Experimental Pharmacology;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3